HealthEquity
HQY
91.90
+0.85
+0.93%
HealthEquity
US · HQY
#1726 by market cap
Listed 1970
91.90
+0.85
+0.93%
Live - 5344 symbols - heartbeat 31s ago
· 2026-10-08 04:02
Pre-market
90.78
-1.22%
After-hours
91.90
0.00%
- Market cap
- 7.60B
- P/E (TTM)i
- 33.18
- P/Bi
- 3.82
- EPSi
- 2.46
- Div yieldi
- 0.00%
- 52W posi
- 55%
Reader sentiment
Are you bullish or bearish on HQY?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.50, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +9.47% YoY
Margins
- Gross margin
- 69.52%
- Operating margin
- 24.93%
- Net margin
- 16.38%
Key ratios & quality
- Enterprise valuei
- 8.25B
- Altman Z-Scorei
- 4.50
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 287.24M | 531.99M | 733.57M | 756.56M | 861.75M | 999.59M | 1.20B | 1.31B |
| Gross profit | 181.19M | 325.91M | 415.33M | 424.77M | 491.94M | 622.64M | 777.26M | 913.12M |
| Selling & admin expenses | 62.54M | 104.51M | 134.46M | 144.04M | 166.32M | 182.93M | 223.00M | 215.17M |
| Research & development | 35.06M | 77.58M | 124.81M | 157.36M | 193.38M | 218.81M | 239.51M | 262.51M |
| Operating profit | 77.67M | 109.12M | 80.00M | 40.57M | 37.65M | 128.13M | 202.87M | 327.48M |
| Pretax profit | 75.82M | 43.16M | 4.14M | -66.74M | -38.10M | 75.04M | 116.03M | 277.43M |
| Tax | 1.92M | 3.49M | -4.69M | -22.45M | -11.95M | 19.33M | 19.33M | 62.23M |
| Net profit | 73.90M | 39.66M | 8.83M | -44.29M | -26.14M | 55.71M | 96.70M | 215.20M |
| Basic EPS | 1 | 1 | 0 | -1 | 0 | 1 | 1 | 3 |
| Diluted EPS | 1.17 | 0.58 | 0.12 | -0.53 | -0.31 | 0.64 | 1.09 | 2.46 |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Revenue | 330.84M | 325.84M | 322.16M | 334.59M | 354.64M | 350.73M |
| Gross profit | 224.31M | 232.60M | 228.06M | 228.15M | 256.31M | 257.95M |
| Selling & admin expenses | 51.52M | 49.91M | 55.29M | 58.45M | 57.96M | 58.08M |
| Research & development | 61.44M | 64.80M | 65.92M | 70.35M | 67.77M | 73.92M |
| Operating profit | 84.35M | 90.88M | 79.85M | 72.40M | 104.07M | 99.66M |
| Pretax profit | 70.95M | 78.05M | 67.53M | 60.90M | 92.41M | 87.87M |
| Tax | 17.04M | 18.19M | 15.84M | 11.16M | 23.00M | 22.22M |
| Net profit | 53.92M | 59.85M | 51.69M | 49.74M | 69.42M | 65.64M |
| Basic EPS | 1 | 1 | 1 | 1 | 1 | 1 |
| Diluted EPS | 0.61 | 0.68 | 0.59 | 0.58 | 0.82 | 0.78 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 394.68M | 297.30M | 460.18M | 351.34M | 382.89M | 557.44M | 477.75M | 512.28M |
| Cash & ST investments | 361.48M | 191.73M | 328.80M | 225.41M | 254.27M | 403.98M | 295.95M | 318.93M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 510.02M | 2.56B | 2.71B | 3.11B | 3.09B | 3.16B | 3.45B | 3.38B |
| Total current liabilities | 29.05M | 151.94M | 204.70M | 153.19M | 131.06M | 117.09M | 156.32M | 156.85M |
| Short-term debt | -- | 51.46M | 76.54M | 20.92M | 27.66M | 9.40M | 10.00M | 9.91M |
| Long-term debt | -- | 1.18B | 924.22M | 922.08M | 907.84M | 874.97M | 1.06B | 957.38M |
| Total liabilities | 32,937,000.00 | 1,534,686,000.00 | 1,331,679,000.00 | 1,254,527,000.00 | 1,193,260,000.00 | 1,128,769,000.00 | 1,333,639,000.00 | 1,273,136,000.00 |
| Total equity | 477.08M | 1.03B | 1.38B | 1.85B | 1.90B | 2.04B | 2.11B | 2.11B |
| Retained earnings | 171.85M | 211.51M | 220.35M | 176.06M | 149.92M | 205.63M | 209.27M | 195.91M |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Total current assets | 472.80M | 492.83M | 498.71M | 512.28M | 466.53M | 460.20M |
| Cash & ST investments | 287.89M | 304.46M | 309.26M | 318.93M | 265.37M | 256.00M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 3.42B | 3.42B | 3.40B | 3.38B | 3.31B | 3.27B |
| Total current liabilities | 116.34M | 116.58M | 120.63M | 156.85M | 135.74M | 153.78M |
| Short-term debt | 9.97M | 9.95M | 9.93M | 9.91M | 9.92M | 9.97M |
| Long-term debt | 1.06B | 1.01B | 982.11M | 957.38M | 942.66M | 931.06M |
| Total liabilities | 1,292,467,000.00 | 1,270,257,000.00 | 1,264,035,000.00 | 1,273,136,000.00 | 1,258,791,000.00 | 1,281,253,000.00 |
| Total equity | 2.12B | 2.15B | 2.13B | 2.11B | 2.05B | 1.99B |
| Retained earnings | 218.35M | 226.90M | 207.94M | 195.91M | 177.20M | 162.58M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 113.42M | 105.01M | 181.62M | 141.00M | 150.65M | 242.83M | 339.86M | 457.09M |
| Depreciation & amortization | 18.19M | 55.35M | 115.90M | 137.19M | 161.20M | 153.08M | 162.45M | 154.66M |
| Free cash flow | 98.38M | 62.94M | 84.66M | 3.91M | 31.52M | 196.75M | -165.60M | 408.32M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 458.50M | 286.78M | 456.64M | 0 | 0 | -121.49M | -299.25M |
| Ending cash balance | 361.48M | 191.73M | 328.80M | 225.41M | 254.27M | 403.98M | 295.95M | 318.93M |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Operating cash flow | 64.74M | 135.87M | 138.58M | 117.92M | 97.53M | 136.16M |
| Depreciation & amortization | 38.74M | 38.45M | 38.78M | 38.68M | 38.21M | 41.96M |
| Free cash flow | 48.60M | 124.69M | 127.19M | 107.84M | 81.23M | 120.39M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -59.07M | -66.75M | -92.42M | -81.02M | -123.31M | -107.74M |
| Ending cash balance | 287.89M | 304.46M | 309.26M | 318.93M | 265.37M | 256.00M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 17.95 | 5.26 | 0.73 | -2.74 | -1.40 | 2.83 | 4.66 | 10.19 |
| ROA %i | 16.81 | 2.58 | 0.33 | -1.52 | -0.84 | 1.78 | 2.92 | 6.30 |
| ROIC %i | 17.95 | 2.77 | 1.40 | -0.79 | 0.20 | 3.00 | 4.38 | 7.91 |
| 5-year avg ROE %i | 14.80 | 11.94 | 10.17 | 7.36 | 3.96 | 0.94 | 0.82 | 2.71 |
| EBIT margin %i | 27.04 | 12.77 | 5.32 | -3.99 | 1.20 | 13.05 | 14.73 | 25.47 |
| FCF / sales %i | 34.25 | 11.83 | 11.54 | 0.52 | 3.66 | 19.68 | -- | 31.09 |
| Current ratioi | 13.58 | 1.96 | 2.25 | 2.29 | 2.92 | 4.76 | 3.06 | 3.27 |
| Quick ratioi | 13.33 | 1.73 | 1.96 | 2.04 | 2.68 | 4.35 | 2.65 | 2.82 |
| Debt / assetsi | 0.00 | 50.73 | 39.66 | 32.45 | 32.20 | 29.49 | 32.14 | 29.63 |
| LT debt / equityi | -- | 121.29 | 72.42 | 53.29 | 51.00 | 45.39 | 51.94 | 47.06 |
| Interest coveragei | -- | 2.74 | 1.12 | -0.82 | 0.21 | 2.35 | 2.91 | 5.86 |
| Revenue CAGR (3Y) %i | 31.34 | 43.94 | 47.30 | 38.10 | 17.44 | 10.86 | 16.61 | 15.08 |
| Net income CAGR (3Y) %i | 64.46 | 14.57 | -42.86 | -- | -- | 84.76 | -- | -- |
| FCF CAGR (3Y) %i | -- | 24.12 | 20.55 | -65.86 | -20.58 | 32.46 | -- | 134.85 |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| ROE %i | 5.77 | 6.78 | 9.01 | 10.19 | 11.06 | 11.43 |
| ROA %i | 3.66 | 4.21 | 5.57 | 6.30 | 6.86 | 7.07 |
| ROIC %i | 5.14 | 5.69 | 7.12 | 7.91 | 8.45 | 8.75 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 17.49 | 19.58 | 23.68 | 25.47 | 26.45 | 26.52 |
| FCF / sales %i | 7.04 | 24.68 | 28.10 | 31.09 | 32.98 | 32.06 |
| Current ratioi | 4.06 | 4.23 | 4.13 | 3.27 | 3.44 | 2.99 |
| Quick ratioi | 3.47 | 3.57 | 3.49 | 2.82 | 2.85 | 2.46 |
| Debt / assetsi | 32.40 | 30.88 | 30.26 | 29.63 | 29.78 | 29.68 |
| LT debt / equityi | 51.64 | 48.69 | 47.72 | 47.06 | 47.61 | 48.29 |
| Interest coveragei | 3.41 | 3.93 | 5.17 | 5.86 | 6.45 | 6.88 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Administration services in connection with health savings accounts (HSAs) and other consumer100.00%
Quote time 2026-10-08 04:02:46 · For reference only, not investment advice and not tailored to your situation.